Test Price
2,800 AED✅ Home Collection Available
CCDC103 Gene Primary Ciliary Dyskinesia (PCD Type 17) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين CCDC103 لخلل الحركة الهدبي الأولي النوع 17 في الإمارات | 2800 درهم | إرشادات هيئة الصحة بدبي 2026
الملخص التنفيذي
- ✔ ضمان الدقة: حساسية تشخيصية تصل إلى 99.9% عبر معالجة بالتسلسل الجيني الفائق ومعتمدة بموجب ISO 9001:2015.
- ✔ الخدمات اللوجستية المميزة: خدمة سحب الدم المنزلي على مستوى المستشفى مع سلسلة تبريد معتمدة ISO، وخدمة Phlebotomy المتنقلة VIP.
- ✔ الإرشاد السريري: استشارة هاتفية بعد الفحص لتفسير النتائج مع أخصائي الوراثة السريرية.
- ✔ التأمين: التحقق المباشر من تغطية التأمين عبر واتساب +971 54 548 8731.
Clinical Overview
The CCDC103 gene test uses next‑generation sequencing (NGS) to identify pathogenic variants causing primary ciliary dyskinesia type 17, an autosomal recessive disorder that disrupts motile cilia and leads to chronic sinopulmonary disease. This definitive molecular diagnosis replaces older electron‑microscopy biopsies and supports personalised management for recurrent otitis, sinusitis, bronchiectasis, and situs inversus (Kartagener syndrome).
يكشف تحليل جين CCDC103 بتقنية التسلسل الجيني المتقدم عن الطفرات المسببة لخلل الحركة الهدبي الأولي، مما يؤكد التشخيص بدقة ويوجه العلاج متعدد التخصصات لمشاكل الأذن والأنف والحنجرة والصدر.
| Feature | Our CCDC103 NGS Test | Closest Alternative (Sanger / TEM Biopsy) |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity – full gene coverage including intron/exon boundaries | Limited to selected exons; may miss deep intronic or large deletions |
| Methodology | Illumina NovaSeq™ NGS with custom bioinformatics pipeline; validation against ClinVar & gnomAD | Single‑gene Sanger sequencing or ciliary ultrastructure analysis via TEM |
| Turnaround | 3‑4 weeks (expedited reporting available) | 6‑12 weeks for biopsy culture & EM; variable for Sanger |
Physician Insight & Safety Protocol
“As an ENT specialist, I witness daily how unrevealed primary ciliary dyskinesia robs children and adults of respiratory health. This NGS test illuminates the genetic root, enabling precise, multidisciplinary care. Correlation with clinical imaging, ciliary beat studies, and family history remains essential — a genetic finding alone does not replace holistic evaluation. Never discontinue bronchodilators, inhaled corticosteroids, or antibiotics without consulting your pulmonologist.”
— Dr. Prabhakar Reddy, DHA License 61713011
⚠ Medication Warning
Do not discontinue prescribed medication without consulting your doctor. This test does not provide immediate treatment recommendations.
Safety Exclusion Criteria
- Minor patients (<18 years) without legal guardian consent (CDS Law 2026)
- Individuals with severe coagulopathy or active bleeding that contraindicates venipuncture
- Inability to provide informed consent or comply with pre‑test genetic counselling
Emergency Red Flags
If you experience sudden severe respiratory distress, hemoptysis, or pleuritic chest pain during the testing period, seek emergency medical care immediately. This genetic is an outpatient diagnostic procedure and does not substitute acute medical intervention.
Patient FAQ & Clinical Guidance
Is a blood draw strictly necessary, or can I use a buccal swab?
Whole blood (3‑5 mL in EDTA tube) is the standard, but we also accept extracted DNA or a single drop of blood on an FTA card; buccal swabs are not validated due to lower DNA yield for NGS.
What does a “positive” result mean for my child’s health?
A positive CCDC103 result confirms the molecular basis of primary ciliary dyskinesia type 17, guiding lifelong respiratory care (chest physiotherapy, aggressive infection management) and informing reproductive options.
هل يمكنني إجراء التحليل بدون وصفة طبية؟
يمكنك التسجيل مباشرة، ولكن يُشترط استشارة استشاري وراثة سريرية لتفسير النتائج وتقديم المشورة الوراثية المتكاملة امتثالاً لقانون المسؤولية الطبية الاتحادي رقم 41 لسنة 2024.
(Translation: You may self‑register, but a clinical geneticist consultation is required for result interpretation and comprehensive genetic counselling, in compliance with Federal Decree‑Law No. 41 of 2024.)
UAE Regulatory & Accreditation Compliance
- Federal Decree‑Law No. 41 of 2024 (Medical Liability) – Article 87 adverse event reporting.
- CDS Law 2026 – strict minor consent and data handling for genetic testing.
- UAE PDPL – genetic data treated as sensitive personal information, encrypted and stored within UAE borders.
- Laboratory accredited to ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
- DHA Facility License 9834453.
For direct insurance billing verification, WhatsApp +971 54 548 8731.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians